Prime Medicine, Inc. (PRME) Dividend History

Prime Medicine, Inc. (PRME) is a biotechnology company focused on developing gene editing therapies for genetic diseases. Leveraging its Prime Editing technology, the company aims to create precise, efficient, and versatile treatments to address a range of genetic conditions, with an emphasis on improving patient outcomes through innovative genomic editing solutions.

60 First St., Cambridge, MA, 02141
Phone: 617-465-0013
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
September 12, 2019 $0.80 09/10/2019 09/11/2019
June 28, 2019 $0.20 06/14/2019 06/17/2019
December 31, 2018 $0.21 12/18/2018 12/19/2018
September 28, 2018 $0.23 09/14/2018 09/17/2018
June 29, 2018 $0.15 06/21/2018 06/22/2018
Show more

Dividends Summary

  • Prime Medicine, Inc. has issued 15 dividend payments over the past 4 years
  • The most recent dividend was paid 2095 days ago, on September 12, 2019
  • The first recorded dividend was paid on December 31, 2015
  • The highest dividend payout was $0.86 per share
  • The average dividend over this 4 year span is $0.26 per share
  • Prime Medicine, Inc. has increased its dividend payments by 820.60% since 2015

Company News

  • Prime Medicine, a clinical-stage biotech company, announced a new preclinical program targeting alpha-1 antitrypsin deficiency, a genetic disorder affecting lung and liver function. Investors reacted positively to the company's plans to file an Investigational New Drug Application by mid-2026, but the development risks associated with clinical-stage biotechs remain.

    The Motley Fool
  • Prime Medicine announced a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder. The program leverages Prime Medicine's proprietary Prime Editing technology and is expected to file an IND/CTA in mid-2026.

    GlobeNewswire Inc.
  • Prime Medicine reported progress in its Wilson's Disease program, including in vivo data demonstrating efficient correction of disease-causing mutations. The company also announced a strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies and expects to report initial data from its Phase 1/2 trial of PM359 for p47phox CGD in 2025.

    GlobeNewswire Inc.
    Featured Companies: BMY
  • Prime Medicine, a biotechnology company, announced that it will participate in several upcoming healthcare conferences, including the Guggenheim Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference. The company is focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform.

    GlobeNewswire Inc.
  • This article discusses a diverse set of growth stocks in various industries, including AI, space, biotech, and emerging technologies. The author highlights the potential rewards and risks of investing in individual growth stocks, and provides an overview of 14 stocks in his tax-advantaged portfolios.

    The Motley Fool
    Featured Companies: ACHR ASPN CRSP GE HWM JOBY KTOS LUNR NVDA NVTS PLTR RKLB
Dividend data last updated 06/07/2025 07:44:06 UTC